Cardiovascular adverse events associated with smoking-cessation pharmacotherapies. Curr Cardiol Rep 2015 Jan;17(1):554
Date
11/21/2014Pubmed ID
25410148DOI
10.1007/s11886-014-0554-8Scopus ID
2-s2.0-84923069679 (requires institutional sign-in at Scopus site) 4 CitationsAbstract
Smoking continues to be the leading cause of preventable deaths in the USA, accounting for one in every five deaths every year, and cardiovascular (CV) disease remains the leading cause of those deaths. Hence, there is increasing awareness to quit smoking among the public and counseling plays an important role in smoking cessation. There are different pharmacological methods to help quit smoking that includes nicotine replacement products available over the counter, including patch, gum, and lozenges, to prescription medications, such as bupropion and varenicline. There have been reports of both nonserious and serious adverse CV events associated with the use of these different pharmacological methods, especially varenicline, which has been gaining media attention recently. Therefore, we systematically reviewed the various pharmacotherapies used in smoking cessation and analyzed the evidence behind these CV events reported with these therapeutic agents.
Author List
Sharma A, Thakar S, Lavie CJ, Garg J, Krishnamoorthy P, Sochor O, Arbab-Zadeh A, Lichstein EMESH terms used to index this publication - Major topics in bold
BenzazepinesBupropion
Chest Pain
Dose-Response Relationship, Drug
Humans
Hypertension
Nicotinic Agonists
Practice Guidelines as Topic
Quinoxalines
Randomized Controlled Trials as Topic
Seizures
Smoking Cessation
Smoking Prevention
Tachycardia
Varenicline
